
By using direct transcriptomics, we identified a new DNA damage repair gene‐associated signature with predictive value for trabectedin efficacy in soft‐tissue sarcoma (STS). Patients in the high‐risk gene signature group showed a significantly worse progression‐free survival compared to patients in the low‐risk group. These findings may help in identifying new therapeutic targets that could enhance the efficacy of trabectedin in STS.
Like
Save
Share